AstraZeneca

AZN: 7,217.00 -58.00 (-0.80%) delayed: 13 Dec 2019, 18:45

Trade now

AstraZeneca News

Broker Forecast - Barclays Capital issues a broker note on AstraZeneca PLC
Fri 13 Sep 2019 10:10

Barclays Capital today reaffirms its overweight investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 8200p (from 8000p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
>> Read more >>
Broker Forecast - Citigroup issues a broker note on AstraZeneca PLC
Wed 11 Sep 2019 08:10

Citigroup today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 10000p (from 7000p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
>> Read more >>
Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLC
Mon 09 Sep 2019 09:50

Deutsche Bank today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 7800p (from 7600p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
>> Read more >>
AstraZeneca says lung cancer treatment reduced death rates by 27%
Mon 09 Sep 2019 08:56

AstraZeneca said results from a clinical trial showed its lung cancer drug reduced the risk of death by more than a fifth in patients with previously-untreated extensive-stage small cell lung cancer. Imfinzi in combination with four cycles of standard-of-care (SoC) chemotherapy - etoposide with either cisplatin or carboplatin - had demonstrated a 'statistically-significant and clinically-meaningful improvement in OS (overall survival) versus SoC consisting of up to six cycles of...
>> Read more >>
Broker Forecast - Barclays Capital issues a broker note on AstraZeneca PLC
Fri 06 Sep 2019 12:40

Barclays Capital today reaffirms its overweight investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 8000p (from 7800p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
>> Read more >>
AstraZeneca lung cancer treatment gets regulatory nod in China
Wed 04 Sep 2019 07:41

AstraZeneca said its lung cancer drug received marketing approval in China as a 1st-line treatment based on results from a clinical trial. In the Flaura trial, 1st-line use of lung cancer drug Tagrisso provided a statistically-significant and clinically- meaningful improvement in progression-free survival, increasing the time patients lived without disease progression or death by a median of 18.9 months versus 10.2 months for those taking standard epidermal growth factor receptor (EGFR)...
>> Read more >>
UK stocks hold on to gains at close
Mon 02 Sep 2019 16:22

UK stocks held on to earlier gains on Monday in what is set to be a pivotal week for British politics, as Boris Johnson faces potential attacks on his aggressive Brexit strategy and possibly his leadership from Tory rebels. At 1610, the benchmark FTSE 100 index was up 94.22 points, or 1.3%, at 7.301.40. The pound remained under pressure from the Brexit ructions, providing a translational benefit for companies with business offshore. Pharmaceuticals company AstraZeneca rose 2.9% to £75.33...
>> Read more >>
UK stocks add to gains at midday
Mon 02 Sep 2019 11:50

UK stocks added to earlier gains on Monday in what is set to be a pivotal week for British politics, as Boris Johnson faces potential attacks on his aggressive Brexit strategy and possibly his leadership from Tory rebels. At 1140, the benchmark FTSE 100 index was up 95.63 points, or 1.3%, at 7.302.81. The pound remained under pressure from the Brexit ructions, providing a translational benefit for companies with business offshore. Pharmaceuticals company AstraZeneca rose 2.1% to 7,474p...
>> Read more >>
UK stocks open 0.6% higher as Brexit drama intensifies
Mon 02 Sep 2019 09:03

UK stocks opened higher on Monday in what is set to be a pivotal week for British politics, as Boris Johnson faces potential attacks on his aggressive Brexit strategy and possibly his leadership from Tory rebels. At 0854, the benchmark FTSE 100 index was up 41.66 points, or 0.6%, at 7.248.84. The pound remained under pressure from the Brexit ructions, providing a translational benefit for companies with business offshore. Pharmaceuticals company AstraZeneca rose 2.1% to 7,474p after it...
>> Read more >>
Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLC
Mon 02 Sep 2019 08:40

Deutsche Bank today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 7600p (from 7200p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
>> Read more >>
AstraZeneca diabetes drug combined with standard care shows reduction in heart failure
Mon 02 Sep 2019 07:28

AstraZeneca said its type-2 diabetes drug on top of standard care showed a reduction in both the incidence of cardiovascular death and the worsening of heart failure in patients with and without type-2 diabetes. The trial of Farxiga (dapagliflozin) on top of standard of care showed a 30% decrease in the risk of experiencing a first episode of worsening heart failure and an 18% decrease in the risk of dying from cardiovascular causes, the company said. The trial results also showed a...
>> Read more >>
AstraZeneca announces 'positive' results from clinical trial
Mon 02 Sep 2019 07:18

AstraZeneca announced 'positive' results from its trial which showed that its cardiovascular drug, when combinbed with Aspirin, reduced the relative risk of heart attack or stroke by 10% compared with aspirin alone. The overall themis trial population included patients with coronary artery disease (CAD) and type-2 diabetes (T2D) with no prior heart attack or stroke. The trial also showed a 15% relative risk reduction for Brilinta plus aspirin for the composite of CV death, heart attack,...
>> Read more >>
FTSE firms thanks to sterling weakness boost
Thu 29 Aug 2019 16:46

UK stocks climbed on Thursday amid weaker sterling, which fell in response to UK prime minister Boris Johnson's decision on Wednesday to prorogue parliament ahead of the Brexit deadline. Investors were also encouraged by China's fresh comments on potentially resolving the trade dispute with the US, while Italian shares enjoyed a relief rally on the return of Giuseppe Conte as the head of a new Italian coalition. At 16:30, the benchmark FTSE 100 was up 68 points, or 0.96% higher, at 7,182.7....
>> Read more >>
FTSE boosted by sterling weakness
Thu 29 Aug 2019 11:51

UK stocks are climbing on Thursday amid weaker sterling, which fell in response to UK prime minister Boris Johnson's decision on Wednesday to prorogue parliament ahead of the Brexit deadline. Investors are also encouraged by China's fresh comments on potentially resolving the trade dispute with the US. At 11:30, the benchmark FTSE 100 was up 82 points, or 1.2% higher, at 7,197. LARGE AND MID CAP RISERS AND FALLERS AstraZeneca added 1.6% to trade at £7.38 after its lupus drug met its...
>> Read more >>
UK stocks lifted by sterling weakness
Thu 29 Aug 2019 09:26

UK stocks are climbing on Thursday amid weaker sterling, which fell in response to UK prime minister Boris Johnson's decision on Wednesday to prorogue parliament ahead of the Brexit deadline. At 08:58, the benchmark FTSE 100 was 0.67%, or 48.01 points, higher at 7,162.72. AstraZeneca added 1.20% to £7.35 after its lupus drug met its primary goal in a clinical trial. International software product group Micro Focus International plummeted 29.07% to 1,103.20p after it revised its full-year...
>> Read more >>
AstraZeneca lupus drug meets primary goal in clinical trial
Thu 29 Aug 2019 07:14

AstraZeneca said its lupus drug had met its primary goal in a clinical trial. The Phase III Tulip 2 trial for anifrolumab, a potential new medicine for the treatment of systemic lupus erythematosus (SLE), met its primary endpoint, achieving a 'statistically-significant and clinically-meaningful reduction in disease activity versus placebo, with both arms receiving standard of care,' the company said. The reduction was measured using the British Isles Lupus Assessment Group based...
>> Read more >>
AstraZeneca eosinophilic asthma treatment gets orphan drug designation
Wed 28 Aug 2019 07:47

AstraZeneca said its severe eosinophilic asthma treatment had received orphan drug designation from US Food and Drug Administration. The FDA grants orphan drug designation (ODD) status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. 'Eosinophilic oesophagitis is an allergic inflammatory disease that can affect children and adults, and typically patients experience a...
>> Read more >>
AstraZeneca lung disease treatment meets primary goal
Wed 28 Aug 2019 07:20

AstraZeneca revealed positive results from its clinical trial for its triple-combination drug for lung disease sufferers. The trial met its primary endpoint showing that the company's triple-combination treatment reduced the risk of severe or moderate exacerbations in patients with chronic obstructive pulmonary disease (COPD), compared with dual-combination therapies. 'Exacerbations are devastating events for patients and can lead to a permanent loss of lung function,' said Mene...
>> Read more >>
UK market accelerates decline as US open fails to lift Fed rate rise doubts
Thu 22 Aug 2019 17:05

UK share markets plunged farther and faster in late afternoon trade to close firmly in the red as a slow start to US trading failed to lift ongoing worries over US interest rate cuts following the release of minutes from the Federal Reserve's last policy meeting. Worries about the fragility of the global economy were also evident in data from Europe on Thursday, where Germany's private sector continued to struggle in August. The negative tone dragged on key commodity markets too with oil...
>> Read more >>
Fed rate worries continue to drag on UK markets, buyout talk rallies NMC Health
Thu 22 Aug 2019 12:14

UK share markets continue their decline at midday on Thursday as uncertainty over the outlook for US interest rate cuts following the release of minutes from the Federal Reserve's last policy meeting kept investors on edge. Worries about the fragility of the global economy were also evident in data from Europe on Thursday, where Germany's private sector continued to struggle in August. But the negative tone was not so evident in key commodity markets with oil prices making modest gains. At...
>> Read more >>
UK stocks fall as market digests Fed minutes
Thu 22 Aug 2019 09:37

UK stocks are falling on Thursday as the market digested the Wednesday's Federal Reserve July meeting minutes, which provided little clarity for future direction. At 08:58, the benchmark FTSE 100 was 0.40%, or 28.72 points, lower at 7,175.25. Antofagasta slipped 0.66% to 813.80p even as it said core earnings jumped in the first half of the year amid higher copper sales volumes, though falling copper prices kept a lid on growth. The miner also said the outlook on the copper market remained...
>> Read more >>
AstraZeneca buys US Food and Drug Administration priority review voucher for $95m
Thu 22 Aug 2019 07:32

AstraZeneca said it had agreed to buy a US Food and Drug Administration priority review voucher for $95m in cash from a subsidiary of Swedish Orphan Biovitrum. The voucher would give the company access to FDA priority review of a single new drug application or biologics license application, reducing the target review time and may potentially lead to an expedited approval. The transaction remained subject to clearance under the Hart-Scott Rodino (HSR) Antitrust Improvements Act, the...
>> Read more >>
AstraZeneca's anaemia treatment given regulatory nod in China
Thu 22 Aug 2019 07:31

AstraZeneca said its drug to treat anaemia in non-dialysis-dependent patients suffering from chronic kidney disease had received marketing authorisation in China. 'With this approval for roxadustat in China, we are now able to provide this first-in-class medicine to all patients living with chronic kidney disease who experience anaemia, regardless of whether they require dialysis,' said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D. The application was filed by...
>> Read more >>
FTSE 100 rises with markets in the mood to rally
Wed 21 Aug 2019 16:42

Wednesday finished as another positive session for the US and European indices, ahead of the Fed meeting minutes, with investors increasingly confident that central banks will step in to try and avert a recession, although sterling fell against both the dollar and the euro amid continuing Brexit-related anxieties. At 16.30, the benchmark FTSE 100 index finished 72.3 points higher at 7,197.3, a 1.01% gain on a relatively quiet day for corporate announcements. LARGE AND MID CAP RISERS &...
>> Read more >>
FTSE 100 firms ahead of US rates guidance
Wed 21 Aug 2019 11:42

UK stocks opened higher on Wednesday following a mixed lead from Asian exchanges, as investors braced for the release of US Fed minutes later in the day that could offer hints on the direction of interest rates. At 11.30, the benchmark FTSE 100 index was up 75 points at 7,200, or 1.05%, on a relatively quiet day for corporate announcements. LARGE AND MID CAP RISERS & FALLERS Pharmaceutical company AstraZeneca edged 0.8% higher to 7,328p despite announcing that a lung cancer treatment...
>> Read more >>
UK stocks open 0.5% higher as investors await US rates guidance
Wed 21 Aug 2019 08:47

UK stocks opened higher on Wednesday following a mixed lead from Asian exchanges, as investors braced for the release of US Fed minutes later in the day that could offer hints on the direction of interest rates. At 0837, the benchmark FTSE 100 index was up 39.17 points, or 0.6%, at 7.164.17, on a relatively quiet day for local company news. Pharmaceutical company AstraZeneca fell 0.4% to 7,242p after announcing that a lung cancer treatment failed to improve survival rates compared with...
>> Read more >>
AstraZeneca combination lung cancer treatment fails to meet primary goal
Wed 21 Aug 2019 07:26

AstraZeneca said a clinical trial of its lung cancer treatment failed to meet its primary goal of improving survival rates compared with chemotherapy. In the primary analysis population of patients whose blood tumour mutational burden was 20 or more mutations per megabase, the combination of AstraZeneca's Imfinzi and tremelimumab did not meet the primary endpoint of improving overall survival compared to standard of care chemotherapy, the company said. The Neptune trial was a...
>> Read more >>
FTSE falls after Italian PM resigns
Tue 20 Aug 2019 16:38

UK stocks reversed their earlier gains to close well into the red on Tuesday after the resignation of Italian Prime Minister Giuseppe Conte opened a can of worms for markets across Europe. Also not helping the UK's leading index was the mid-afternoon gain in the pound, which made up ground from its midday losses against the euro and dollar to end the day broadly flat against both currencies. The benchmark FTSE 100 index closed 0.9%, or 64.65 points, lower at 7,125. LARGE AND MID CAP...
>> Read more >>
FTSE stays higher with pound under pressure
Tue 20 Aug 2019 12:02

UK stocks remained higher on Tuesday as fears of a looming no-deal Brexit continued to heap pressure on the pound, helping exporters. Sterling clawed back a little ground on the dollar and euro, but was still significantly down with Brexit noise set to continue throughout the day as European Union officials respond to remarks from UK Prime Minister Boris Johnson. At 1152, the benchmark FTSE 100 index was up 26.65 points, or 0.37%, at 7,216.40. LARGE AND MID CAP RISERS AND FALLERS...
>> Read more >>
UK stocks open 0.5% higher; pound under pressure
Tue 20 Aug 2019 08:59

UK stocks opened higher on Tuesday as fears of a looming no-deal Brexit continued to heap pressure on the pound, helping exporters. At 0852, the benchmark FTSE 100 index was up 35.38 points, or 0.5%, at 7.225.03. Mining giant BHP fell 1.3% to 1,758.6p, despite declaring a record annual dividend, as its profits fell short of market expectations and it warned of an uncertain economic outlook marred by trade tensions. Services company Wood Group gained 1.6% to 458.1p on news that it had sold...
>> Read more >>
AstraZeneca type-2 diabetes drug meets primary objective
Tue 20 Aug 2019 07:21

AstraZeneca said results from a clinical trial of its type-2 diabetes drug to treat patients with heart failure met its primary objective after showing a reduction of cardiovascular death or the worsening of heart failure when added to standard of care, compared to a placebo. The trial was conducted in patients with reduced ejection fraction on standard of care treatment, including those with and without type-2 diabetes. 'With the DAPA-HF trial, Farxiga becomes the first in its class to...
>> Read more >>
Broker Forecast - Barclays Capital issues a broker note on AstraZeneca PLC
Fri 16 Aug 2019 08:30

Barclays Capital today reaffirms its overweight investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 7800p (from 7600p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
>> Read more >>
Broker Forecast - UBS issues a broker note on AstraZeneca PLC
Wed 14 Aug 2019 09:40

UBS today reaffirms its sell investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 5700p (from 5400p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
>> Read more >>
AstraZeneca's leukaemia drug wins fast-track review from US Food and Drug Administration
Wed 14 Aug 2019 07:21

AstraZeneca said the US Food and Drug Administration had granted breakthrough therapy designation for its chronic lymphocytic leukaemia drug. The breakthrough therapy designation (BTD) status for Calquence, administered as a monotherapy treatment for adult patients with chronic lymphocytic leukaemia, was granted following positive results from the interim analyses of the Elevate-Tn and Ascend Phase III clinical trials. An FDA BTD was designed to accelerate the development and regulatory...
>> Read more >>
AstraZeneca and Merck ovarian cancer drug meets primary endpoint in clinical trial
Wed 14 Aug 2019 07:14

AstraZeneca and Merck said their ovarian cancer drug combined with bevacizumab had improved survival rates, meeting its primary goal during clinical trials. Women who took Lynparza plus bevacizumab lived longer without disease progression or death versus those taking bevacizumab alone, the company said. 'The positive results from the PAOLA-1 trial demonstrate a clear potential benefit of adding Lynparza to the standard-treatment bevacizumab for women with advanced ovarian cancer,'...
>> Read more >>
Cocktail of risks sours FTSE 100 performance
Fri 09 Aug 2019 16:45

A combination of economic and political risks in Italy, Asia the US and UK helped heap pressure on global equity markets on Friday. The FTSE 100 was not exempt, despite some support from weaker sterling, falling 0.4% to 7,253.85. The subdued sentiment saw the US S&P 500 slip 1.1% to 2,904.27 by 4.30pm UK time. LARGE AND MID CAP RISERS AND FALLERS Advertising giant WPP rallied 7.5% to 983.6p, even as it booked a 44% slide in first-half profit, owing to shrinking margins and a one-off...
>> Read more >>
FTSE gathers some ground after GDP-inspired fall for the pound
Fri 09 Aug 2019 12:08

A weaker than expected UK GDP print put pressure on sterling which in turn lifted the export-heavy FTSE 100. Although still just about in the red, the index was off its lows at 7,280.76. Fading optimism over trade relations between the US and China is expected to see US markets give back some of yesterday's big gains when trading resumes later. LARGE AND MID CAP RISERS AND FALLERS Advertising giant WPP rallied 7% to 979.4p, even as it booked a 44% slide in first-half profit, owing to...
>> Read more >>
AstraZeneca reveals positive results from trial of lung cancer drug
Fri 09 Aug 2019 07:46

AstraZeneca announced positive results from its clinical trial for its metastatic non-small cell lung cancer drug, which had 'significantly improved survival rates. Tagrisso showed a statistically-significant and clinically-meaningful improvement in overall survival, a secondary endpoint in the FLAURA Phase III trial, compared with erlotinib or gefitinib both of which were previous standard-of-care treatments in this setting, the company said. The Flaura trial met its primary endpoint...
>> Read more >>
AstraZeneca and Merck prostate cancer drug meets primary endpoint in clinical trial
Wed 07 Aug 2019 07:12

AstraZeneca and Merck said their castration-resistant prostate cancer drug had met its primary endpoint in clinical trials. The trial of Lynparza had shown showed a statistically-significant and clinically-meaningful improvement in the primary endpoint of radiographic progression-free survival versus enzalutamide or abiraterone in men with metastatic castration-resistant prostate cancer. The safety and tolerability profile of Lynparza was generally consistent with previous trials, the...
>> Read more >>
Broker Forecast - Goldman Sachs issues a broker note on AstraZeneca PLC
Tue 06 Aug 2019 09:10

Goldman Sachs today reaffirms its sell investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 5500p (from 5000p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
>> Read more >>
AstraZeneca's type-2 diabetes drug label updated in EU with positive outcomes, data from trial
Mon 05 Aug 2019 07:33

AstraZeneca said the European Commission had approved an update to the marketing authorisation for the company's type-2 diabetes drug to include positive results from a phase 3 drug trial. In the Phase III DECLARE-TIMI 58 trial, the company's type 2 diabetes drug Forxiga achieved a statistically-significant reduction in the composite endpoint of hospitalisation for heart failure or cardiovascular death versus placebo, one of the two primary efficacy endpoints, AztraZenec said. There were...
>> Read more >>
Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLC
Mon 29 Jul 2019 08:30

Deutsche Bank today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 7200p (from 6900p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
>> Read more >>
Broker Forecast - Barclays Capital issues a broker note on AstraZeneca PLC
Fri 26 Jul 2019 09:50

Barclays Capital today reaffirms its overweight investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 7600p (from 7500p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
>> Read more >>
FTSE down as ECB warns on outlook
Thu 25 Jul 2019 16:43

The FTSE 100 again closed below the 7,500 mark on Thursday after the European Central Bank hinted at an interest rate cut in September. It kept interest rates unchanged, but in a news conference, ECB boss Mario Draghi said the outlook is getting 'worse and worse' for the Eurozone economy, particularly for manufacturing, and hinted at cutting rates in September to tackle a potential economic slowdown. The benchmark index of UK stocks closed 0.17%, or 12.41 points, lower at 7,489.05. LARGE...
>> Read more >>
FTSE dips ahead of possible ECB rate cut
Thu 25 Jul 2019 11:58

UK stocks have dipped slightly from early morning trading on Thursday as investors cautiously wait to see whether the European Central Bank will cut interest rates this afternoon. At 11:51, the benchmark FTSE 100 was up 0.11%, or 8.79 points, at 7,510.25. LARGE AND MID CAP RISERS AND FALLERS Aveva was last seen up 1.16% at £40.04 after it said revenue growth in the first quarter was low double-digit amid 'strong' rental subscription growth and a boost from favourable foreign currency...
>> Read more >>
UK stocks rise ahead of ECB interest rate decision
Thu 25 Jul 2019 09:38

UK stocks are edging higher on Thursday morning as investors await the outcome of the European Central Bank's latest interest rate decision later in the session. At 08:58, the benchmark FTSE 100 was up 0.26%, or 19.39 points, at 7,520.85. Aveva was last seen up 1.31% at 4,010p after it said revenue growth in the first quarter was low double-digit amid 'strong' rental subscription growth and a boost from favourable foreign currency movements. British-Dutch consumer goods major Unilever...
>> Read more >>
AstraZeneca lifts product sales guidance amid stronger H1
Thu 25 Jul 2019 07:31

AstraZeneca upgraded its product sales guidance as an acceleration in second-quarter sales bolstered its first-half performance. Product sales in 2019 were now expected to increase by a low double-digit percentage; the prior guidance was for a high single-digit percentage increase. The upgraded outlook followed the stronger performance in the first half and the return to product sales growth in H2 2018, the company said. First-half product sales grew 12% (17% at constant currency)...
>> Read more >>
FTSE regains its poise by lunchtime
Mon 15 Jul 2019 12:07

The FTSE 100 was up by midday, advancing 0.2% to 7,520.77 after slipping into the red earlier. Investors apparently focused on the positive elements of China's latest growth figures, announced overnight. Retailers were in the doghouse after weak industry figures and insurance stocks also took some heat as the market reacted to changes in the way compensation awards to accident victims are calculated. Direct Line shares fell 0.7%, paring heavier initial losses. LARGE AND MID CAP RISERS AND...
>> Read more >>
UK stocks open slightly higher after mixed Chinese economic data
Mon 15 Jul 2019 08:57

UK stocks opened slightly higher on Monday after the release of a mixed set of Chinese data that showed economic growth slowing but better-than-expected industrial output and retail sales. At 0850, the benchmark FTSE 100 index was up 3.29 points at 7.509.26. Sports Direct International sank 12% after the sportswear and equipment retailer delayed the release of its results, blaming the House of Fraser integration process and regulatory scrutiny. Copper miner Antofagasta advanced 4.7% on...
>> Read more >>
AstraZeneca's Type-1 diabetes treatment fails to get FDA approval
Mon 15 Jul 2019 07:42

AstraZeneca said the U.S. Food and Drug Administration had decided against approving the company's application for its diabetes drug. The drugmaker said it would work closely with the FDA to discuss the next steps after receiving a complete response letter from the US health regulator declining its application for using Farxiga. Farxiga was recently approved in Europe (5mg) and Japan (5mg, potential up-titration to 10mg) under the name Forxiga, as an adjunct to insulin in adults with type-1...
>> Read more >>

<< Previous << Page 2 >> Next >>

Data provided by

and

Prices quoted have a delay of at least 15 minutes. You may receive a different price (which may be higher or lower) when an instruction is executed. Though all reasonable efforts are made to present accurate data, Equiniti Financial Services Limited and third party data providers accept no responsibility for the correctness, completeness or accuracy of the data provided.
Where past performance details are included this is not a reliable indicator of future performance. Short-term past performance of less than one year is a particularly unreliable indicator.